Iovance shares surge 256% as 2026 revenue outlook lifts cancer-drug demand
AI Summary- Iovance Biotherapeutics shares became the top-performing U.S. mid-cap stock during the third quarter.
- 256% was the share-price increase, while 2026 revenue guidance reached $410 million-$420 million.
- Iovance is scheduled to announce third-quarter earnings early in November 2026.